SARS‐CoV‐2 vaccination in patients with paroxysmal nocturnal hemoglobinuria: An Italian multicenter survey

Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2

“…The major warning in this setting is that of boosting complement activity thus inducing breakthrough hemolytic flares (BTH). BTH was reported in about 3% of PNH patients after SARS-CoV-2 vaccines [ [103] , [104] , [105] ] and in about 10% of CAD [ 106 ], managed conservatively in most cases.…”

SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria

“…PNH-related complications in those on complement inhibitors in our cohort were moderate, similar reports conclude up to a 14% breakthrough hemolysis risk in patients undergoing vaccination. 8 , 15 This is manageable, but requires physician vigilance and patient education. Advising patients with PNH to receive vaccines within the first half of complement inhibitor treatment schedule is preferable to reduce risks of breakthrough hemolysis e.g., within 1 week post eculizumab, within 4 weeks post ravulizumab.…”

Efficacy of anti‐severe acute respiratory syndrome coronavirus 2 mRNA vaccines in adults with severe acquired aplastic anemia with or without allogeneic hematopoietic stem cell transplantation

“…Aplastic anemia (AA) [ 4 ] represents another immunocompromised situation. Surprisingly, the incidence of COVID‐19 infection in this setting appears to be relatively low (2.5%–13%) [ 5 , 6 ], despite most patients being still on immunotherapy. This could be related to favorable host factors, such as young age, or be secondary to some protective immune dysregulation known to be present in AA [ 7 ].…”